WealthPlan Investment Management LLC Sells 17,905 Shares of Danaher Corporation $DHR

Key Points

• WealthPlan Investment Management LLC has reduced its holdings in Danaher Corporation by 88.6%, from 20,219 shares to 2,314 shares, impacting their total investment to approximately $457,000.
• Danaher reported a quarterly earnings per share of $1.80, exceeding estimates, with revenue of $5.94 billion, which is a 3.4% year-over-year increase.
• The company announced a quarterly dividend of $0.32 per share, with an ex-dividend date set for September 26th and a current dividend yield of 0.6%.

WealthPlan Investment Management LLC trimmed its position in Danaher Corporation (NYSE:DHR - Free Report) by 88.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,314 shares of the conglomerate's stock after selling 17,905 shares during the quarter. WealthPlan Investment Management LLC's holdings in Danaher were worth $457,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. grew its holdings in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares in the last quarter. Sierra Ocean LLC grew its holdings in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares in the last quarter. Red Tortoise LLC grew its holdings in Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock valued at $30,000 after buying an additional 98 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Danaher in the 1st quarter valued at $31,000. Finally, Dunhill Financial LLC grew its holdings in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR stock opened at $210.86 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The company has a market cap of $150.99 billion, a P/E ratio of 44.86, a P/E/G ratio of 2.94 and a beta of 0.77. The business has a fifty day simple moving average of $201.43 and a 200 day simple moving average of $197.23.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the prior year, the company earned $1.72 EPS. Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Weiss Ratings reissued a "hold (c-)" rating on shares of Danaher in a report on Wednesday, October 8th. Barclays reissued an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Finally, Rothschild & Co Redburn reissued a "neutral" rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $244.60.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.